☆ 4.6 Article

Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack

Yuan Fang et al.

Summary: This study showed that overexpression of MCT4 in HCC is associated with poor prognosis. Inhibition of MCT4 can suppress tumor growth, enhance immune cell infiltration and cytotoxicity. Furthermore, MCT4 inhibition can improve the therapeutic effect of anti-PD-1 immunotherapy and prolong survival in mice.

HEPATOLOGY (2023)

Add to Collection

Article Immunology

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients

Guosheng Yuan et al.

Summary: This study developed and validated a radiomics nomogram that successfully predicted the treatment efficacy of anti-PD-1 therapy in HCC patients by combining pretreatment CT images and clinical factors. The nomogram showed good performance in both training and validation cohorts, indicating its clinical utility and consistency.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?

Erminia Romano et al.

Summary: Radiotherapy (RT) is highly effective at killing tumor cells and has additional immunomodulatory properties that can potentially improve its efficacy and cancer outcomes when combined with immunotherapy. Combining RT with immunomodulatory agents aims to enhance anti-tumor immune responses and improve treatment responses and patient outcomes. Important questions need to be addressed for effective clinical translation of RT and immunotherapy combinations, including optimal RT dose, target volume, choice of immuno-oncology agents, administration routes, and schedules.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study

Liyun Zheng et al.

Summary: The study compared the efficacy and safety of TACE+Sor group and TACE+Sor+ICIs group in treating intermediate and advanced TACE-refractory HCC, showing that TACE+Sor+ICIs group had a higher disease control rate and prolonged PFS and OS.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Add to Collection

Article Immunology

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma

Xin Li et al.

Summary: In conclusion, the combination of anti-angiogenic therapy and immune checkpoint inhibitors with cryoablation is of great significance for patients with advanced HCC, effectively controlling the disease.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study

Zhigang Fu et al.

Summary: Combination treatment with TACE and lenvatinib shows significant improvement in clinical outcomes for unresectable HCC patients with manageable safety profile. The efficacy of this combination treatment should be further validated in prospective studies with larger sample size.

HEPATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Oncology

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Fei Cao et al.

Summary: TACE combined with lenvatinib plus sintilimab is an effective and safe therapeutic regimen for unresectable hepatocellular carcinoma, showing high objective response rate, duration of response, progression-free survival, and overall survival.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)

Jian Lu et al.

Summary: Establishing a global guideline with consensus from experts representing east and west may help address the practice variations of TACE for HCC. The international expert panel convened to summarize a standard consensus on TACE, covering aspects such as patient selection, procedure performance, and treatment outcomes. Evidences suggest better outcomes with combined TACE strategies, such as combining with local therapies or PD-1/PD-L1 plus TKI agents, especially for patients at high risk of tumor recurrence or TACE failure/refractory.

HEPATOBILIARY SURGERY AND NUTRITION (2021)

Add to Collection

Article Oncology

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma

Liting Zhong et al.

Summary: The combination of PD-1/PD-L1 inhibitors with palliative radiotherapy and anti-angiogenic therapy appears to be safe and effective in treating hepatocellular carcinoma, with a significant impact on patient survival. Further studies are needed to explore the clinical benefits of this triple therapy approach.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

Jingjing Guo et al.

Summary: The study showed that TACE treatment led to a decrease in CD4(+)/CD8(+) cell ratio and an increase in PD1 gene expression in HCC patients. Expression levels of PD1 and PD-L1 were associated with TACE treatment outcomes and patient prognosis.

ONCOLOGY LETTERS (2021)

Add to Collection

Article Oncology

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma

Yu-Jie Xu et al.

Summary: The study compared the efficacy and safety of toripalimab plus hepatic arterial infusion chemotherapy (HAIC) and lenvatinib in advanced HCC patients. Results showed that the TorHAIC group had better outcomes in terms of PFS, OS, disease control rate, and ORR compared to the lenvatinib group, with acceptable safety profiles for both treatments. Propensity score-matched analysis also supported the superiority of the TorHAIC group.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists

Bin-Yan Zhong et al.

Summary: The study found significant differences in the recognition of TACE failure/refractoriness among Chinese clinicians, with most agreeing on the need for redefining this concept. Some clinicians chose to use TACE-based combination therapy after TACE failure.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2021)

Add to Collection

Article Immunology

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression

Liang Wen et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

Jinzhang Chen et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis

Dominik Bettinger et al.

LIVER CANCER (2019)

Add to Collection

Article Oncology

Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma

Po-Chien Shen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Add to Collection

Article Oncology

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

Chi-Leung Chiang et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Radiotherapy for HCC: Ready for prime time?

Andrew Bang et al.

JHEP REPORTS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Article Oncology

Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma

Eli Sapir et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata et al.

HEPATOLOGY INTERNATIONAL (2017)

Add to Collection

Article Gastroenterology & Hepatology

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2

Tadaaki Arizumi et al.

DIGESTIVE DISEASES (2017)

Add to Collection

Review Gastroenterology & Hepatology

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

Jordi Bruix et al.

GASTROENTEROLOGY (2016)

Add to Collection

Article Oncology

Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma

Daniel R. Wahl et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Michael B. Bernstein et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma

Tadaaki Arizumi et al.

LIVER CANCER (2015)

Add to Collection

Article Gastroenterology & Hepatology

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

et al.

JOURNAL OF HEPATOLOGY (2015)

Add to Collection

Review Oncology

Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update

Masatoshi Kudo et al.

ONCOLOGY (2014)

Add to Collection

Article Oncology

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma

Alexis Bujold et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors

Erqi Liu et al.

TRANSLATIONAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization

Jin-Kyu Kang et al.

CANCER (2012)

Add to Collection

Article Gastroenterology & Hepatology

Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma

Hwi Young Kim et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand

E. Terzi et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Management of Hepatocellular Carcinoma: An Update

Jordi Bruix et al.

HEPATOLOGY (2011)

Add to Collection

Article Gastroenterology & Hepatology

Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

Kazumasa Hiroishi et al.

JOURNAL OF GASTROENTEROLOGY (2010)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict et al.

MEDICAL PHYSICS (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.